These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene]. Pchelina SN; emel'ianov AK; Usenko TS Mol Biol (Mosk); 2014; 48(1):3-14. PubMed ID: 25842821 [TBL] [Abstract][Full Text] [Related]
10. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390 [TBL] [Abstract][Full Text] [Related]
11. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502 [TBL] [Abstract][Full Text] [Related]
12. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Higashi S; Moore DJ; Colebrooke RE; Biskup S; Dawson VL; Arai H; Dawson TM; Emson PC J Neurochem; 2007 Jan; 100(2):368-81. PubMed ID: 17101029 [TBL] [Abstract][Full Text] [Related]
13. LRRK2 expression is enriched in the striosomal compartment of mouse striatum. Mandemakers W; Snellinx A; O'Neill MJ; de Strooper B Neurobiol Dis; 2012 Dec; 48(3):582-93. PubMed ID: 22850484 [TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Smith WW; Pei Z; Jiang H; Moore DJ; Liang Y; West AB; Dawson VL; Dawson TM; Ross CA Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18676-81. PubMed ID: 16352719 [TBL] [Abstract][Full Text] [Related]
15. Low-variance RNAs identify Parkinson's disease molecular signature in blood. Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808 [TBL] [Abstract][Full Text] [Related]
16. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Westerlund M; Belin AC; Anvret A; Bickford P; Olson L; Galter D Neuroscience; 2008 Mar; 152(2):429-36. PubMed ID: 18272292 [TBL] [Abstract][Full Text] [Related]
17. Mouse models for LRRK2 Parkinson's disease. Xu Q; Shenoy S; Li C Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430 [TBL] [Abstract][Full Text] [Related]
18. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048 [TBL] [Abstract][Full Text] [Related]
19. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts. Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304 [TBL] [Abstract][Full Text] [Related]
20. Enhanced dendritogenesis and axogenesis in hippocampal neuroblasts of LRRK2 knockout mice. Paus M; Kohl Z; Ben Abdallah NM; Galter D; Gillardon F; Winkler J Brain Res; 2013 Feb; 1497():85-100. PubMed ID: 23270607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]